CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($) $ in Millions		Total		Preferred Stock [Member]	Common Stock [Member]	Add'l Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accum. Other Comp. Loss [Member]	Shareholders' Equity [Member]	Noncontrolling Interests [Member]
Beginning balance (in shares) at Dec. 31, 2018	[1]			478	9,332,000,000		3,615,000,000
Beginning balance at Dec. 31, 2018	[1]	$ 63,758		$ 19	$ 467	$ 86,253	$ (101,610)	$ 89,554	$ (11,275)	$ 63,407	$ 351
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	8,945	[2],[3],[4]					8,929		8,929	15
Other comprehensive income/(loss), net of tax	[1]	(262)	[2]						(260)	(260)	(2)
Cash dividends declared:
Common stock	[1]	(4,062)						(4,062)		(4,062)
Preferred stock	[1]	(1)						(1)		(1)
Noncontrolling interests	[1]	(8)									(8)
Share-based payment transactions (in shares)	[1]				31,000,000		7,000,000
Share-based payment transactions	[1]	402			$ 2	712	$ (312)			402
Purchases of common stock (in shares)	[1]						(180,000,000)
Purchases of common stock	[1]	(8,865)					$ (8,865)			(8,865)
Preferred stock conversions and redemptions (in shares)	[1]			(20)
Preferred stock conversions and redemptions	[1]	(2)		$ (1)		(1)				(2)
Other	[1],[5]	19						19		19
Ending balance (in shares) at Jun. 30, 2019	[1]			458	9,363,000,000		3,801,000,000
Ending balance at Jun. 30, 2019	[1]	59,924		$ 18	$ 468	86,963	$ (110,786)	94,440	(11,535)	59,568	357
Beginning balance (in shares) at Mar. 31, 2019	[1]			466	9,358,000,000		3,801,000,000
Beginning balance at Mar. 31, 2019	[1]	59,158		$ 19	$ 468	86,635	$ (110,781)	93,388	(10,923)	58,806	352
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	5,056	[2],[3],[4]					5,046		5,046	10
Other comprehensive income/(loss), net of tax	[1]	(610)	[2]						(613)	(613)	3
Cash dividends declared:
Common stock	[1]	(3,994)						(3,994)		(3,994)
Preferred stock	[1]	0						0		0
Noncontrolling interests	[1]	(8)									(8)
Share-based payment transactions (in shares)	[1]				5,000,000
Share-based payment transactions	[1]	324			$ 0	329	$ (6)			324
Purchases of common stock (in shares)	[1]						0
Purchases of common stock	[1]	0					$ 0			0
Preferred stock conversions and redemptions (in shares)	[1]			(8)
Preferred stock conversions and redemptions	[1]	(1)		$ 0		(1)				(1)
Other	[1]	0						0		0
Ending balance (in shares) at Jun. 30, 2019	[1]			458	9,363,000,000		3,801,000,000
Ending balance at Jun. 30, 2019	[1]	59,924		$ 18	$ 468	86,963	$ (110,786)	94,440	(11,535)	59,568	357
Beginning balance (in shares) at Dec. 31, 2019	[1]			431	9,369,000,000		3,835,000,000
Beginning balance at Dec. 31, 2019	[1]	63,447	[6]	$ 17	$ 468	87,428	$ (110,801)	97,670	(11,640)	63,143	303
Beginning balance (in shares) at Dec. 31, 2019	[1]			431	9,369,000,000		3,835,000,000
Beginning balance at Dec. 31, 2019	[1]	63,447	[6]	$ 17	$ 468	87,428	$ (110,801)	97,670	(11,640)	63,143	303
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	6,845	[2],[3],[4]					6,828		6,828	17
Other comprehensive income/(loss), net of tax	[1]	(1,617)	[2]						(1,605)	(1,605)	(12)
Cash dividends declared:
Common stock	[1]	(4,294)						(4,294)		(4,294)
Preferred stock	[1]	0						0		0
Noncontrolling interests	[1]	(80)									(80)
Share-based payment transactions (in shares)	[1]				25,000,000		6,000,000
Share-based payment transactions	[1]	266			$ 1	473	$ (208)			266
Purchases of common stock (in shares)	[1]						0
Purchases of common stock	[1]	0					$ 0
Preferred stock conversions and redemptions (in shares)	[1],[7]			(431)			(1,000,000)
Preferred stock conversions and redemptions	[1],[7]	(1)		$ (17)		(15)	$ 31			(1)
Other (in shares)	[1]						0
Other	[1]	0				0		0		0	0
Ending balance (in shares) at Jun. 28, 2020	[1]			0	9,394,000,000		3,840,000,000
Ending balance at Jun. 28, 2020	[1]	64,564	[6]	$ 0	$ 470	87,886	$ (110,978)	100,203	(13,246)	64,336	228
Beginning balance (in shares) at Mar. 29, 2020	[1]			417	9,393,000,000		3,841,000,000
Beginning balance at Mar. 29, 2020	[1]	65,338		$ 17	$ 470	87,680	$ (111,010)	101,000	(13,131)	65,026	312
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	3,434	[2],[3],[4]					3,426		3,426	8
Other comprehensive income/(loss), net of tax	[1]	(127)	[2]						(115)	(115)	(12)
Cash dividends declared:
Common stock	[1]	(4,223)						(4,223)		(4,223)
Preferred stock	[1]	0						0		0
Noncontrolling interests	[1]	(80)									(80)
Share-based payment transactions (in shares)	[1]				2,000,000		0
Share-based payment transactions	[1]	222			$ 0	221	$ 1			222
Purchases of common stock (in shares)	[1]						0
Purchases of common stock	[1]	0					$ 0			0
Preferred stock conversions and redemptions (in shares)	[1],[7]			(417)			(1,000,000)
Preferred stock conversions and redemptions	[1],[7]	0		$ (17)		(14)	$ 31			0
Other	[1]	0						0		0	0
Ending balance (in shares) at Jun. 28, 2020	[1]			0	9,394,000,000		3,840,000,000
Ending balance at Jun. 28, 2020	[1]	$ 64,564	[6]	$ 0	$ 470	$ 87,886	$ (110,978)	$ 100,203	$ (13,246)	$ 64,336	$ 228

[1] Amounts may not add due to rounding.

[2] Amounts may not add due to rounding.

[3] Amounts may not add due to rounding.

[4] Amounts may not add due to rounding.

[5] The increase to Retained earnings represents the cumulative effect of the adoption of a new accounting standard in the first quarter of 2019 for leases. For additional information, see Notes to Consolidated Financial Statements––Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2019 in our 2019 Financial Report.

[6] Amounts may not add due to rounding.

[7]   On May 4, 2020, all outstanding shares of Pfizer’s Series A convertible perpetual preferred stock were converted into shares of Pfizer common stock. See Note 11. Equity for additional information.